Physician profile
Kavitha Narayanan
NPI 1487128344
$2,823.41
in general payments reported to CMS, 2019-2025
23 companies · $264 in 2025
The $264 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $900 · 2022: $836 · 2023: $605 · 2024: $219 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $601 · Education: $487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $600.51 |
| Education | $486.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $652.99 | 2021-2023 | |
| Astellas Pharma US INC | $495.73 | 2021-2025 | Padcev |
| Merck Sharp & Dohme LLC | $312.36 | 2021-2025 | Keytruda, Keytruda Qlex |
| Lilly USA, LLC | $265.98 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Exelixis INC. | $231.89 | 2021-2023 | |
| Eisai INC. | $133.68 | 2021-2025 | |
| Genzyme Corporation | $114.36 | 2021 | |
| Abbvie INC. | $114.08 | 2022-2023 | |
| Amgen INC. | $98.09 | 2021-2022 | |
| Tersera Therapeutics LLC | $43.89 | 2021 | |
| Agios Pharmaceuticals, INC. | $39.49 | 2024-2025 | Pyrukynd |
| Janssen Biotech, INC. | $35.69 | 2025 | Rybrevant |
| Deciphera Pharmaceuticals INC. | $33.06 | 2022-2023 | Qinlock |
| Novartis Pharmaceuticals Corporation | $31.66 | 2022 | |
| Celgene Corporation | $29.91 | 2023 | Pomalyst |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $29.42 | 2022 | |
| Seagen INC. | $28.41 | 2023 | Tukysa |
| Puma Biotechnology, INC. | $27.97 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $24.88 | 2021 | |
| Aadi Bioscience, INC. | $24.03 | 2023 | Fyarro |
| Syndax Pharmaceuticals, INC. | $22.58 | 2025 | |
| Array Biopharma INC | $18.36 | 2025 | Mektovi, Braftovi, Xalkori |
| Janssen Pharmaceuticals, INC | $14.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kavitha Narayanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.